A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder
<h3>Background</h3><p dir="ltr">Anxiety disorders are among the most common comorbid mental disorders in children and adolescents with attention-deficit hyperactivity disorder (ADHD). While the role of atomoxetine, a non-stimulant medication, is well-established in the ma...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Published: |
2022
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513536191889408 |
|---|---|
| author | Mohamed Adil Shah Khoodoruth (14589828) |
| author2 | Sami Ouanes (9617363) Yasser Saeed Khan (17191735) |
| author2_role | author author |
| author_facet | Mohamed Adil Shah Khoodoruth (14589828) Sami Ouanes (9617363) Yasser Saeed Khan (17191735) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohamed Adil Shah Khoodoruth (14589828) Sami Ouanes (9617363) Yasser Saeed Khan (17191735) |
| dc.date.none.fl_str_mv | 2022-09-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.ridd.2022.104275 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/A_systematic_review_of_the_use_of_atomoxetine_for_management_of_comorbid_anxiety_disorders_in_children_and_adolescents_with_attention-deficit_hyperactivity_disorder/24745098 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Psychology Clinical and health psychology attention-deficit hyperactivity disorder ADHD child and adolescent psychiatry stimulant non-stimulant atomoxetine comorbidity ADHD and anxiety anxiety psychopharmacotherapy management systematic review |
| dc.title.none.fl_str_mv | A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Background</h3><p dir="ltr">Anxiety disorders are among the most common comorbid mental disorders in children and adolescents with attention-deficit hyperactivity disorder (ADHD). While the role of atomoxetine, a non-stimulant medication, is well-established in the management of ADHD symptoms since two decades, there is a dearth of evidence regarding its efficacy in the management of anxiety disorders in children and adolescents with ADHD.</p><h3>Aims</h3><p dir="ltr">We aimed to provide insights into (1) the comparative efficacy of atomoxetine in children and adolescents with comorbid ADHD and anxiety disorders, (2) change in severity of anxiety symptoms based on patients’, parents’, and clinicians’ ratings, (3) tolerability and side effects.</p><h3>Methods</h3><p dir="ltr">We searched PubMed, EMBASE, and PsycINFO for clinical trials that addressed the efficacy of atomoxetine for anxiety symptoms in children and adolescents with ADHD. All published literature was systematically reviewed.</p><h3>Results</h3><p dir="ltr">We included four studies, out of which two specifically addressed comorbid ADHD and anxiety disorder. The studies suggested that atomoxetine did not exacerbate and in fact reduced anxiety symptoms in young patients with comorbid ADHD.</p><h3>Conclusions and implications</h3><p dir="ltr">Overall, atomoxetine demonstrates good efficacy in improving anxiety symptoms in children and adolescents with ADHD. Further studies are needed to shed light on atomoxetine’s efficacy for anxiety subtypes in ADHD.</p><h2>Other Information</h2><p dir="ltr">Published in: Research in Developmental Disabilities<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.ridd.2022.104275" target="_blank">https://dx.doi.org/10.1016/j.ridd.2022.104275</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_f6901a8c949893a2e45a0e56f6baaca7 |
| identifier_str_mv | 10.1016/j.ridd.2022.104275 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/24745098 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorderMohamed Adil Shah Khoodoruth (14589828)Sami Ouanes (9617363)Yasser Saeed Khan (17191735)Biomedical and clinical sciencesClinical sciencesPsychologyClinical and health psychologyattention-deficit hyperactivity disorderADHDchild and adolescent psychiatrystimulantnon-stimulantatomoxetinecomorbidityADHD and anxietyanxietypsychopharmacotherapymanagementsystematic review<h3>Background</h3><p dir="ltr">Anxiety disorders are among the most common comorbid mental disorders in children and adolescents with attention-deficit hyperactivity disorder (ADHD). While the role of atomoxetine, a non-stimulant medication, is well-established in the management of ADHD symptoms since two decades, there is a dearth of evidence regarding its efficacy in the management of anxiety disorders in children and adolescents with ADHD.</p><h3>Aims</h3><p dir="ltr">We aimed to provide insights into (1) the comparative efficacy of atomoxetine in children and adolescents with comorbid ADHD and anxiety disorders, (2) change in severity of anxiety symptoms based on patients’, parents’, and clinicians’ ratings, (3) tolerability and side effects.</p><h3>Methods</h3><p dir="ltr">We searched PubMed, EMBASE, and PsycINFO for clinical trials that addressed the efficacy of atomoxetine for anxiety symptoms in children and adolescents with ADHD. All published literature was systematically reviewed.</p><h3>Results</h3><p dir="ltr">We included four studies, out of which two specifically addressed comorbid ADHD and anxiety disorder. The studies suggested that atomoxetine did not exacerbate and in fact reduced anxiety symptoms in young patients with comorbid ADHD.</p><h3>Conclusions and implications</h3><p dir="ltr">Overall, atomoxetine demonstrates good efficacy in improving anxiety symptoms in children and adolescents with ADHD. Further studies are needed to shed light on atomoxetine’s efficacy for anxiety subtypes in ADHD.</p><h2>Other Information</h2><p dir="ltr">Published in: Research in Developmental Disabilities<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.ridd.2022.104275" target="_blank">https://dx.doi.org/10.1016/j.ridd.2022.104275</a></p>2022-09-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.ridd.2022.104275https://figshare.com/articles/journal_contribution/A_systematic_review_of_the_use_of_atomoxetine_for_management_of_comorbid_anxiety_disorders_in_children_and_adolescents_with_attention-deficit_hyperactivity_disorder/24745098CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/247450982022-09-01T00:00:00Z |
| spellingShingle | A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder Mohamed Adil Shah Khoodoruth (14589828) Biomedical and clinical sciences Clinical sciences Psychology Clinical and health psychology attention-deficit hyperactivity disorder ADHD child and adolescent psychiatry stimulant non-stimulant atomoxetine comorbidity ADHD and anxiety anxiety psychopharmacotherapy management systematic review |
| status_str | publishedVersion |
| title | A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder |
| title_full | A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder |
| title_fullStr | A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder |
| title_full_unstemmed | A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder |
| title_short | A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder |
| title_sort | A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder |
| topic | Biomedical and clinical sciences Clinical sciences Psychology Clinical and health psychology attention-deficit hyperactivity disorder ADHD child and adolescent psychiatry stimulant non-stimulant atomoxetine comorbidity ADHD and anxiety anxiety psychopharmacotherapy management systematic review |